Appili gets FDA approval to expand the clinical trial of favipiravir
Category: #health  By Pankaj Singh  Date: 2020-08-11
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Appili gets FDA approval to expand the clinical trial of favipiravir

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application for favipiravir, a broad-spectrum antiviral. The company has planned to expand the second phase of the clinical trials of this antiviral into the U.S., intending to evaluate the safety and efficacy of favipiravir tablets towards controlling outbreaks after exposure to COVID-19 in long-term care facilities.

According to Dr. Armand Balboni, the CEO of Appili Therapeutics, the burden of disease in long-term care facilities continues to be a major issue, and finding ways to provide LTC staff and residents with protection against COVID-19 via an oral treatment would be a remarkable milestone in efforts to contain the devastating effects of this pandemic. He has further highlighted that the limited response to the vaccine is frequently observed in elderly people and this has been the chief reason for expanding the trial into the U.S.

Also, favipiravir would be administered in the oral form as a tablet, without the requirement to be given in the intravenous mode, and might prove to be a significant option for avoiding and controlling outbreaks in elderly people living in LTC centers, added Balboni.

As reported, the company’s Phase 2 clinical trials focus on leveraging whether favipiravir could be suitably administered as an oral tablet across a broad range of long-term care settings. The company has planned to enroll up to 760 participants in this second phase of clinical trials across both Canada and the U.S.

Dr. Allison McGeer, Senior Clinician Scientist, Lunenfeld-Tanenbaum Research Institute, Sinai Health, has stated that, while the highest risk for contracting the disease lies with the elderly people, the currently surging rates of COVID-19 infection as evident in much of the U.S. are expected to be a major threat to people working and living in long-term care settings.

 

Source Credits:

https://www.businesswire.com/news/home/20200810005098/en/FDA-Clears-Appili-Therapeutics-Expand-Phase-2

 



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

PCS Software adds new contactless features to expand TMS platform

PCS Software adds new contactless features to expand TMS platform

By Pankaj Singh

  • With this addition, it is now possible for PCS consumers to effectively manage their workflows using their mobile devices
  • Document digitization has...

ODP teams up with Microsoft to support shared & new B2B customers

ODP teams up with Microsoft to support shared & new B2B customers

By Pankaj Singh

The ODP Corporation, an American retail company, has recently announced the expansion of its long-standing relationship with Microsoft. The two companies are planning to boost efficiencies and growth of their shared as...

Gannex reveals positive data from ASC41 clinical study in 20 subjects

Gannex reveals positive data from ASC41 clinical study in 20 subjects

By Pankaj Singh

Ascletis Pharma Inc.’s wholly-owned company, Gannex, has reportedly announced the positive clinical data from its ASC41 trial conducted among overweight and obese subjects. The active metabolite of this liver-tar...